CJC-1295 (No DAC) / Ipamorelin Blend

1. Product Overview

Specification

Detail

Product Name

CJC-1295 (No DAC) / Ipamorelin Blend

Grade

Research Grade

Composition

Dual-Peptide Formulation (CJC-1295 (No DAC) and Ipamorelin)

Batch Number

2025007

Form

Lyophilized Powder

Purity (HPLC)

≥98%

2. Description

This research blend combines two potent growth hormone secretagogues (GHS) designed specifically for investigational use into the synergistic stimulation of the somatotropic (Growth Hormone, GH) axis. The formulation is intended to amplify GH secretion through distinct but complementary mechanistic pathways.

Peptide Components

• Ipamorelin: A selective agonist of the ghrelin/Growth Hormone Secretagogue (GHS) receptor. Its action is focused on elevating baseline GH levels by mimicking the action of ghrelin, but without significantly increasing levels of appetite-stimulating hormones or cortisol at standard research concentrations.
• CJC-1295 (No DAC): A modified peptide analog of Growth Hormone Releasing Hormone (GHRH). By binding to the GHRH receptor, this component functions to amplify the natural amplitude of the GH pulses released by the pituitary gland. The "No DAC" designation signifies a short half-life, which preserves the pulsatile nature of natural GH release, making it ideal for simulating physiological GH dynamics.

Synergistic Mechanism

The combination is investigated for its potential to elicit a significantly "amplified" GH secretory response when compared to the administration of either peptide alone. This synergy is hypothesized to result from:

1. GHRH Receptor Activation (CJC-1295): Provides the signal for GH release from somatotrophs.
2. Ghrelin Receptor Activation (Ipamorelin): Primes the somatotrophs to be more responsive to the GHRH signal and suppresses the inhibitory effects of somatostatin.

The goal of this blend is to maximize the investigational potential for GH axis modulation while potentially limiting proportional increases in common GHS-related side effects, such as increased prolactin or cortisol.

3. Physical and Chemical Data

3.1. Structure and Sequence

Peptide

Sequence

Molecular Formula

Molecular Weight

CJC-1295 (No DAC)

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

C152H252N44O42

3367.97 g/mol

Ipamorelin

Aib-His-D-2-Nal-Phe-Lys-NH2

C38H49N9O5

711.86 g/mol

3.2. Specifications

Parameter

Specification

Analysis Method

Purity

≥98%

High-Performance Liquid Chromatography (HPLC)

Appearance

White Lyophilized Powder

Visual Inspection

Water Content

<5%

Karl Fischer Titration

Peptide Content

≥80%

UV Spectrophotometry / Amino Acid Analysis

4. Handling and Storage

4.1. Storage Instructions

Condition

Storage Temperature

Duration

Unreconstituted (Lyophilized)

-20°C to -80°C

Up to Date (Recommended: 2 years)

Reconstituted

2°C to 8°C (Refrigerated)

Recommended: 4 weeks

4.2. Handling Precautions

• This product is for RESEARCH USE ONLY and is not intended for human or animal use, diagnostic procedures, or therapeutic applications.
• Wear appropriate personal protective equipment (PPE), including gloves, safety glasses, and a lab coat, when handling the lyophilized powder or reconstituted solution.
• Avoid inhalation of the powder and direct contact with skin and eyes.
• Material Safety Data Sheet (MSDS) is available upon request.

5. Reconstitution Protocol

5.1. Recommended Solvent

Bacteriostatic Water for Injection (BWFI) is recommended for reconstitution to ensure stability and minimize microbial growth during refrigerated storage.

5.2. Procedure

1. Allow the vial to reach room temperature before opening.
2. Using a sterile syringe, slowly draw the desired amount of BWFI. A common research concentration requires adding 1-2 mL of solvent per vial.
3. Inject the solvent gently down the side of the vial. DO NOT inject directly onto the lyophilized powder cake.
4. Gently swirl the vial until the powder is fully dissolved. DO NOT SHAKE the vial vigorously, as this can degrade the peptide structure.
5. Store the reconstituted solution refrigerated at 2°C to 8°C.

6. Applications in Research

This dual-peptide blend is a valuable tool for research areas including:

• Endocrinology: Investigating the complex feedback loops and regulatory mechanisms of the GH-IGF-1 axis.
• Pharmacodynamics: Studying the combined kinetic and dynamic effects of GHRH and GHS analogs.
• Metabolic Studies: Exploring the impact of pulsatile GH secretion on lipid metabolism, glucose homeostasis, and body composition in various in vivo models.
• Aging and Tissue Repair: Researching the role of sustained, physiological GH pulse amplitude in tissue regeneration and mitigating age-related somatopause.

7. Quality Assurance Documentation

The quality of Batch Number 2025007 is verified through rigorous analytical testing. The Certificate of Analysis, including raw HPLC and Mass Spectrometry data, is provided to ensure transparency and reliability for research purposes.

Please refer to the enclosed Certificate of Analysis for Batch 2025007: File.

8. Ordering and Support

For technical inquiries regarding the use and stability of this research blend, or to schedule a consultation with a product specialist, please contact Person at Person@researchlabs.com.

For placing a new order, please visit the online ordering portal: File.

Disclaimer

This product is sold strictly for research purposes only. It is not a drug, dietary supplement, cosmetic, or food. Research use means the use of the product in vitro or in vivo animal research models only. Purchasers must be legally permitted to handle and use research-grade chemicals and peptides. By purchasing this product, the user acknowledges and agrees that they are responsible for ensuring its safe and lawful use. The manufacturer makes no claims regarding the use of this material for human or animal consumption.